Immunotherapy / PD-1 inhibitorPhase 3 trialInvestigational
Durvalumab
How it works
Blocks the PD-1 protein on immune cells, allowing them to recognize and attack cancer cells.
Cancer types
Lung Cancer— All patients
Colorectal Cancer— All patients
Pancreatic Cancer— All patients
Ovarian Cancer— All patients
Efficacy
Durvalumab has shown promise in improving response rates and survival in ovarian cancer patients, with a median overall survival of approximately 22 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Investigating Durvalumab and Oleclumab for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Savolitinib and Durvalumab Combination for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Durvalumab and Radiation Therapy for Early-stage Non-Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Durvalumab After Chemoradiation Therapy for Limited Stage Small-Cell Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Testing Chemo-Immunotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Durvalumab and Tremelimumab in Metastatic Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing New Treatments for Advanced Triple-Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Assessing Durvalumab and Domvanalimab in Stage III Unresectable NSCLC | Lung Cancer | phase-3 | — | Source → |
| Testing Durvalumab and Radiation Therapy in Early Stage Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Durvalumab Maintenance in Frail Small Cell Lung Cancer Patients | Lung Cancer | phase-2 | — | Source → |
| Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Durvalumab, Trastuzumab, and Pertuzumab in HER2-Enriched Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Combination Therapy for Resectable Pancreatic Cancer Before Surgery | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Ceralasertib in Combination with Other Treatments for Various Cancers | Prostate Cancer | phase-2 | — | Source → |
| Study of AZD2811 and Durvalumab in Small-Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Evaluating Pumitamig and Durvalumab in Lung Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Testing Radiotherapy and Immunotherapy for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| New Cancer Treatment Combination Shows Promise in Lung and Head and Neck Cancers | Lung Cancer | phase-1 | Five (8.3%) patients had objective responses; 31 (51.7%) had stable disease. | Source → |
| Durvalumab as Consolidation for Limited Stage Small Cell Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Combining two treatments for advanced prostate cancer | Prostate Cancer | phase-2 | Median radiographic progression-free survival was 5.0 months, and median overall survival was 19.1 months. | Source → |
| Durvalumab and Chemotherapy Tested in Lung Cancer Patients | Lung Cancer | phase-2 | Confirmed ORR was 16% (80% confidence interval: 7-30); response was maintained for more than 6 months in the four patients with confirmed response. | Source → |
| Triplet Combination of Targeted Immunotherapeutic Agents for Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Durvalumab's Effect on Lung Cancer Recurrence After Chemotherapy and Radiation | Lung Cancer | phase-3 | Durvalumab receipt was associated with improved PFS (median 16 vs. 11 months, P = .011) and improved OS (median 50 vs. 30 months, P = .042). | Source → |
| Durvalumab Study for Unresectable Lung Cancer in Russia | Lung Cancer | preclinical | — | Source → |
| Combining Chemotherapy and Immunotherapy for Lung Cancer | Lung Cancer | phase-2 | N2 nodal clearance was 73.3% (22/30) after treatment. | Source → |
| Advanced Lung Cancer Treatment Study Underway | Lung Cancer | phase-3 | — | Source → |
| Trial Tests Cancer Treatments | Colorectal Cancer | phase-2 | — | Source → |
| Pancreatic Cancer Treatment Trial | Pancreatic Cancer | phase-1 | — | Source → |
| Durvalumab treatment linked to pneumonitis risk in lung cancer patients | Lung Cancer | observational | — | Source → |
| Durvalumab-Induced Lung Injury Complicated by Human Metapneumovirus Infection | Lung Cancer | observational | — | Source → |
| Timing of Durvalumab Treatment Affects Lung Cancer Survival | Lung Cancer | observational | When considering the timing of durvalumab, no significant survival difference was found when durvalumab was initiated on or before week 4: adjusted HR, 0.81 (95% CI, 0.62 to 1.05, = .07). | Source → |
| New Treatment Combination Shows Promise for Ovarian Cancer Patients | Ovarian Cancer | phase-2 | PFS36 rates are 47.4% (olaparib priming then olaparib-durvalumab), 48.7% (olaparib-cyclophosphamide then olaparib-durvalumab), and 35.1% (olaparib monotherapy). | Source → |
| Durvalumab and Radiation Therapy Improve Lung Cancer Outcomes | Lung Cancer | phase-3 | The 2- and 3-year local control rates in patients who received total radiation doses > 66 Gy were 80% and 75%, respectively. | Source → |
| Rare Cancer Linked to New Lung Cancer Treatment | Leukemia | observational | — | Source → |
| Durvalumab as Consolidation Therapy for Lung Cancer Patients in Brazil | Lung Cancer | observational | Median progression-free survival was 9.9 months, with a 36 month-PFS of 34.5%. | Source → |
| New Lung Cancer Treatment Shows Promise After Surgery | Lung Cancer | observational | The IPTW-adjusted median progression-free survival was 25.4 months for the CRT-D group, and 11.5 months for the CRT group. | Source → |
| Durvalumab with Radiation Therapy in Lung Cancer: Early Results | Lung Cancer | phase-2 | The primary endpoint of progression-free survival at 12 months was 20%. | Source → |
| Durvalumab Outcomes in Stage III Lung Cancer Patients | Lung Cancer | observational | The 4-year overall survival rate was 53% overall, and 67% for patients with a PD-L1 score of ≧50%. | Source → |
| Durvalumab treatment for lung cancer patients shows promising results | Lung Cancer | observational | Median progression-free survival was 16.7 months (95% CI 12.2-25). | Source → |
| Durvalumab Works in Elderly Lung Cancer Patients, but Side Effects are More Common | Lung Cancer | observational | The median progression-free survival was 17.7 months in patients aged 70 years or older, and 19.4 months in younger patients. | Source → |
| New Trial Explores Combination Therapy for Lung Cancer | Lung Cancer | phase-3 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.